This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
ETF Sectors to Bet on Positive Vaccine News
by Sweta Jaiswal, FRM
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
ETFs to Win/Lose From Thanksgiving Amid COVID-19 Restrictions
by Sanghamitra Saha
Thanksgiving meal is cheaper this year. Spending on Thanksgiving celebrations will likely go up, which should benefit grocers and retailers. However, travels are likely to see a decline due to COVID-19.
6 ETFs to Consider as Thanksgiving Week Begins
by Sweta Jaiswal, FRM
Let's look at some ETFs that are expected to benefit from consumer shopping and celebrations as the Thanksgiving week begins.
Celebrate Thanksgiving Week With These ETFs
by Sweta Killa
Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
ETF Strategies to Play as Vaccine Hopes Firm With Moderna Data
by Sanghamitra Saha
It???s been really a sweet November for the global economy and markets thanks to back-to-back release of upbeat coronavirus vaccine data from Moderna and Pfizer.
Leisure Stocks & ETFs Rally on Strong Vaccine Hopes
by Sanghamitra Saha
Hopes of a sooner-than-expected coronavirus vaccine launch led Wall Street to a record high on Nov 16 .
Biggest ETF Winners from Coronavirus Vaccine News
by Neena Mishra
Promising vaccine results from Pfizer sent economically sensitive stocks soaring
ETFs Riding the Latest Coronavirus Vaccine Optimism Wave
by Sweta Jaiswal, FRM
The coronavirus vaccine progress has brought back optimism for some ETFs, which were largely affected by the outbreak-led slowdown in economic activities.
Vaccine Hopes & Divided Government: Sector ETFs to Win
by Sanghamitra Saha
News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.